Gynaecological cancer: PARP inhibition — moving beyond BRCA-mutated disease


cells with homologous-recombination deficiency (HRD), and PARP inhibitors have proven therapeutic activity in women with BRCA-mutated ovarian cancer. This group, however, accounts for only ~20% of patients with ovarian cancer. Importantly, approximately 30% of women with this disease have HRD of a different aetiology, and might also benefit from PARP… (More)
DOI: 10.1038/nrclinonc.2016.207


  • Presentations referencing similar topics